Milestone Pharmaceuticals (MIST) EBIT: 2020-2021

Historic EBIT for Milestone Pharmaceuticals (MIST) over the last 2 years, with Dec 2021 value amounting to -$43.1 million.

  • Milestone Pharmaceuticals' EBIT fell 5.30% to -$15.0 million in Q3 2022 from the same period last year, while for Sep 2022 it was -$58.8 million, marking a year-over-year change of. This contributed to the annual value of -$43.1 million for FY2021, which is 15.06% up from last year.
  • As of FY2021, Milestone Pharmaceuticals' EBIT stood at -$43.1 million, which was up 15.06% from -$50.7 million recorded in FY2020.
  • Milestone Pharmaceuticals' 5-year EBIT high stood at -$43.1 million for FY2021, and its period low was -$50.7 million during FY2020.
  • Its 2-year average for EBIT is -$46.9 million, with a median of -$46.9 million in 2020.
  • Data for Milestone Pharmaceuticals' EBIT shows a peak YoY rose of 15.06% (in 2021) over the last 5 years.
  • Yearly analysis of 2 years shows Milestone Pharmaceuticals' EBIT stood at -$50.7 million in 2020, then rose by 15.06% to -$43.1 million in 2021.